Cargando…
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331543/ https://www.ncbi.nlm.nih.gov/pubmed/32624257 http://dx.doi.org/10.1016/j.jaci.2020.05.033 |
_version_ | 1783553350155894784 |
---|---|
author | Hosoki, Koa Chakraborty, Abhijit Sur, Sanjiv |
author_facet | Hosoki, Koa Chakraborty, Abhijit Sur, Sanjiv |
author_sort | Hosoki, Koa |
collection | PubMed |
description | The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being “immune” to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration–approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them. |
format | Online Article Text |
id | pubmed-7331543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73315432020-07-06 Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective Hosoki, Koa Chakraborty, Abhijit Sur, Sanjiv J Allergy Clin Immunol Covid-19 The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being “immune” to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration–approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them. American Academy of Allergy, Asthma & Immunology 2020-08 2020-07-02 /pmc/articles/PMC7331543/ /pubmed/32624257 http://dx.doi.org/10.1016/j.jaci.2020.05.033 Text en © 2020 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Covid-19 Hosoki, Koa Chakraborty, Abhijit Sur, Sanjiv Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective |
title | Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective |
title_full | Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective |
title_fullStr | Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective |
title_full_unstemmed | Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective |
title_short | Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective |
title_sort | molecular mechanisms and epidemiology of covid-19 from an allergist’s perspective |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331543/ https://www.ncbi.nlm.nih.gov/pubmed/32624257 http://dx.doi.org/10.1016/j.jaci.2020.05.033 |
work_keys_str_mv | AT hosokikoa molecularmechanismsandepidemiologyofcovid19fromanallergistsperspective AT chakrabortyabhijit molecularmechanismsandepidemiologyofcovid19fromanallergistsperspective AT sursanjiv molecularmechanismsandepidemiologyofcovid19fromanallergistsperspective |